Landon Pediatric Foundation — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$7,000	1
2023	Research	$33,682	4
2022	Research	$150,263	10
2021	Research	$6,126	5
2020	Research	$10,000	1
2019	Research	$558	1

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $193,945 15 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $7,000 1 payment
Insmed, Inc. $6,684 6 payments

Studies the money was for Research payments · program years 2019–2025

A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis $174,495 12 payments
M16-111 $10,000 1 payment
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis $9,450 2 payments
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) $7,000 1 payment
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study $6,126 5 payments
A Randomized, Open-label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment $558 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.